<DOC>
	<DOC>NCT00824356</DOC>
	<brief_summary>This is a placebo-controlled, 3-period crossover study to assess the efficacy and safety of two single doses of an intranasal anti-histamine GSK1004723 compared with placebo in an allergen challenge chamber in male subjects with seasonal allergic</brief_summary>
	<brief_title>Allergen Challenge Chamber Study With Single Dose Intranasal GSK1004723 Compared With Placebo</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Subject is healthy apart from seasonal allergic rhinitis, as determined by a physician. Can have mild asthma. Male Aged 18 65 Weight 50kg+, BMI 1932 kg/m2 Exhibit response to Challenge Chamber and skin prick test. Nonsmoker Capable of giving informed consent No nasal structural abnornmality/polyposis, surgery, infection. any respiratory disease, other than mild asthma or seasonal allergic rhinitis participated in another clinical study within 30 days. Subject has donated a unit of blood within 1 month Use of prescription or nonprescription drugs, including vitamins and st john's wort within 7 days of trial. History of sensitivty to drug History of alcohol/drug abuse within 12 months. Positive Hepatitis B antibody test Positive HIV antibody test Risk of noncompliance with study protocol Perenial allergic rhinitis Administration of oral, injectable or dermal corticosteriods within 8 weeks, intranasal or inhaled within 3 weeks. Past or present disease that may affect outcome, as judge by investigator Specific Immunotherapy within 2 years</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Allergic Rhinitis</keyword>
	<keyword>Proof-of-Concept</keyword>
</DOC>